Bionano Genomics (BNGO) Stock Price

Bionano Genomics Price

NASDAQ·CLOSED
1.32
​
Market closed

Over the last 9 years Bionano Genomics grew revenue by 19.1% annually, reaching 28.21 M USD. For Bionano Genomics, the net margin of -93.6% is up versus -424.7% a few years ago. The consensus 12-month price target for Bionano Genomics is 5.00 USD, about 280.2% above where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.

Bionano Genomics stock price

Access this data via the Eulerpool API

Bionano Genomics business model & stock analysis

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The company is headquartered in San Diego, California and currently employs 147 full-time employees. The company went IPO on 2018-08-01. The firm develops and markets the Saphyr system. The Company’s products include Sequencing for Discovery Research and Cytogenetics. Cytogenetics provide a clinical diagnosis, cytogenetic tests detect known variations that are linked to specific diseases or therapeutic responses. Saphyr system is platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Sequencing for Discovery Research is primarily used to find single nucleotide variations responsible for disease or therapeutic response. The Company’s subsidiary, Lineagen, Inc., provides molecular diagnostics services for individuals.

Frequently asked questions about Bionano Genomics

8 analysts currently rate the Bionano Genomics stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Bionano Genomics to generate revenue of 32.14 M USD and earnings per share of -2.03 USD.

Converted at the current exchange rate, the Bionano Genomics share trades at 1.18 EUR (1.32 USD).

The Bionano Genomics share (BNGO) is listed on 5 stock exchanges, including: NASDAQ (BNGO), London (0A4K.L), Frankfurt (2Y3.F), München (2Y3.MU), Düsseldorf (2Y3.DU).

The expected revenue of Bionano Genomics is 32.14 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Bionano Genomics is -21.79 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Bionano Genomics is currently -0.65. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Bionano Genomics stock.

The price-to-sales ratio (P/S) of Bionano Genomics is currently 0.44. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Bionano Genomics stock.

The Eulerpool Quality Score for Bionano Genomics is 2/10.

The ISIN of Bionano Genomics is US09075F4046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Bionano Genomics is A2JRLZ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Bionano Genomics is BNGO. The ticker symbol is used to trade Bionano Genomics shares on the stock exchange.

Fair ValueTerminal
1.13 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue per Employee
296,947.38 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Aug 1, 2018
ISIN
US09075F4046
Cusip
09075F107
Sedol
BFY8K60
Market capitalization
13.39 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-0.65
P/Ee 2027
-1.43
P/Ee 2028
-2.67
P/Ee 2029
-5.78
P/Ee 2030
6.58
P/S
P/Se
0.44
EV/EBIT
—
P/B Ratio
0.30
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-51.41 %
Last updated Oct 13, 2026, 2:34 AM

Bionano Genomics Ticker

DÜSSELDORF · 2Y3.DUFRANKFURT · 2Y3.FLONDON · 0A4K.LMUNICH · 2Y3.MUNASDAQ · BNGO

All fundamentals and in-depth analysis of Bionano Genomics

Our stock analysis for Bionano Genomics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bionano Genomics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.